tbuckley/cabot-search huggingface dataset:
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
Authors: Daniel Bottomly, Nicola Long, Anna Reister Schultz, Stephen E. Kurtz, Cristina E. Tognon, Kara Johnson, Melissa Abel, Anupriya Agarwal, Sammantha Avaylon, Erik Benton, Aurora Blucher, Uma Borate, Theodore P. Braun, Jordana Brown, Jade Bryant, Russell Burke, Amy Carlos, Bill H. Chang, Hyun Jun Cho, Stephen Christy, Cody Coblentz, Aaron M. Cohen, Amanda d’Almeida, Rachel Cook, Alexey Danilov, Kim-Hien T. Dao, Michie Degnin, James Dibb, Christopher A. Eide, Isabel English, Stuart Hagler, Heath Harrelson, Rachel Henson, Hibery Ho, Sunil K. Joshi, Brian Junio, Andy Kaempf, Yoko Kosaka, Ted Laderas, Matt Lawhead, Hyunjung Lee, Jessica T. Leonard, Chenwei Lin, Evan F. Lind, Selina Qiuying Liu, Pierrette Lo, Marc M. Loriaux, Samuel Luty, Julia E. Maxson, Tara Macey, Jacqueline Martinez, Jessica Minnier, Andrea Monteblanco, Motomi Mori, Quinlan Morrow, Dylan Nelson, Justin Ramsdill, Angela Rofelty, Alexandra Rogers, Kyle A. Romine, Peter Ryabinin, Jennifer N. Saultz, David A. Sampson, Samantha L. Savage, Robert Schuff, Robert Searles, Rebecca L. Smith, Stephen E. Spurgeon, Tyler Sweeney, Ronan T. Swords, Aashis Thapa, Karina Thiel-Klare, Elie Traer, Jake Wagner, Beth Wilmot, Joelle Wolf, Guanming Wu, Amy Yates, Haijiao Zhang, Christopher R. Cogle, Robert H. Collins, Michael W. Deininger, Christopher S. Hourigan, Craig T. Jordan, Tara L. Lin, Micaela E. Martinez, Rachel R. Pallapati, Daniel A. Pollyea, Anthony D. Pomicter, Justin M. Watts, Scott J. Weir, Brian J. Druker, Shannon K. McWeeney, Jeffrey W. Tyner
Journal: Cancer Cell (2022)

Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large cohort of AML patients, which facilitated discovery of functional genomic correlates. Here, we present a dataset that has been harmonized with our initial report to yield a cumulative cohort of 805 patients (942 specimens). We show strong cross-cohort concordance and identify features of drug response. Further, deconvoluting transcriptomic data shows that drug sensitivity is governed broadly by AML cell differentiation state, sometimes conditionally affecting other correlates of response. Finally, modeling of clinical outcome reveals a single gene, PEAR1, to be among the strongest predictors of patient survival, especially for young patients. Collectively, this report expands a large functional genomic resource, offers avenues for mechanistic exploration and drug development, and reveals tools for predicting outcome in AML.
MO22-2 Thromboembolic events associated to COVID-19 in a breast cancer cohort during the most recent waves of the disease
Authors: Jorge Illarramendi, Juan Ignacio Arraras, Gema Asin, Ana Manterola, Katy Paola Zavala, Sonia Flamarique, Esteban Salgado, Susana De La Cruz, Jose Juan Illarramendi
Journal: Annals of Oncology (2022)
P35-7 Analysis of BRCA1/2 mutations for metastatic castration resistant prostate cancer in clinical practice
Authors: Kazutoshi Fujita, Takahito Nakayma, Syunsuke Inoguchi, Saizo Fujimoto, Mamoru Hashimoto, Takashi Kikuchi, Mitsuhisa Nishimoto, Shogo Adomi, Eri Banno, Yoshitaka Saito, Nobutaka Shimizu, Yasunori Mori, Takafumi Minami, Takayuki Takahama, Kimio Yonesaka, Masahiro Nozawa, Kazuhiro Nose, Kazuhiro Yoshimura, Hirotsugu Uemura
Journal: Annals of Oncology (2022)
O13-4 Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION)
Authors: Masahiro Morise, Hiroshi Sakai, Terufumi Kato, Shingo Matsumoto, Toru Kumagai, Tomohiro Sakamoto, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroaki Takeoka, Kenichi Chikamori, Naofumi Shinagawa, Hiroshi Tanaka, Tomonori Hirashima, S Peter Eggleton, Rolf Bruns, Gordon Otto, Paul Paik
Journal: Annals of Oncology (2022)
MO15-5 A proposal of efficient operation of expert panel for genomic medicine by pre-review meeting (pre-EP)
Authors: Masahiro Yoshioka, Tomohiro Kondo, Quy Pham Nguyen, Reiko Kimura-Tsuchiya, Keita Fukuyama, Masashi Kanai, Takeshi Nakajima, Takahiro Yamada, Shigemi Matsumoto, Manabu Muto
Journal: Annals of Oncology (2022)
MO26-2 Intra-tumoral clusters between CD20+ B cells and BCL6+ CD4+ T cells are prognostic in early oral cancers
Authors: Chumut Phathunane, Rebecca Wijers, Maria De Herdt, Senada Koljenovic, Stefan Sleijfer, Robert Baatenburg De Jong, Jose Hardillo, Reno Debets, Hayri Emrah Balcioglu
Journal: Annals of Oncology (2022)
Controlling chronic respiratory diseases in Finland from 1996 to 2018
Authors: Tiina Mattila, Marina Erhola, Tuula Vasankari, Sanna Toppila-Salmi, Fredrik Herse, Riikka-Leena Leskelä, Vesa Jormanainen, Anelma Lammi, Tari Haahtela
Journal: European Respiratory Journal (2022)

<b>A nationwide, long-term and systematic lung health policy has been implemented in Finland. The real-world data indicate that the burden of respiratory diseases has reduced both for patients and, overall, for society.</b>https://bit.ly/3LvPjjv
P20-2 Observational study to evaluate RAS status in ctDNA for mCRC patients with RAS mutant tumor: RASMEX study (JACCRO CC-17)
Authors: Naoki Izawa, Yoshinori Kagawa, Hironaga Satake, Yu Sunakawa, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii
Journal: Annals of Oncology (2022)
P68-3 Phase 2 study comparing the efficacy between afatinib &amp; osimertinib based on immunological biomarker in EGFR-mutant NSCLC
Authors: Kei Morikawa, Hisashi Tanaka, Saori Takata, Satoshi Watanabe, Kazuma Kishi, Kenzo Soejima, Kyoichi Kaira, Hiroshi Kagamu, Kenichi Yoshimura, Noriyuki Matsutani, Nobuhiko Seki
Journal: Annals of Oncology (2022)
P57-7 Inflammatory scores in gastric cancer patients treated with nivolumab: Tokushukai REAl-world Data project 02 (TREAD 02)
Authors: Rai Shimoyama, Yoshinori Imamura, Kiyoaki Uryu, Takahiro Mase, Yoshiaki Fujimura, Maki Hayashi, Megu Ohtaki, Keiko Otani, Nobuaki Shinozaki, Hironobu Minami
Journal: Annals of Oncology (2022)
O12-5 A retrospective analysis of the clinical factors affecting the prognosis of non-seminomatous mediastinal germ cell tumor
Authors: Yosuke Amano, Tatsunori Shimoi, Momoko Tokura, Chiharu Mizoguchi, Shosuke Kita, Kasumi Yamamoto, Shu Yazaki, Hitomi Okuma, Yuki Kojima, Tadaaki Nishikawa, Emi Noguchi, Kazuki Sudo, Kan Yonemori
Journal: Annals of Oncology (2022)
MO45-3 The efficacy of osimertinib in patients with EGFR-positive non-small cell lung cancer with malignant pleural effusion
Authors: Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Journal: Annals of Oncology (2022)
MO45-1 Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia
Authors: Yosuke Kagawa, Kaname Nosaki, Shingo Matsumoto, Terufumi Kato, Atushi Nakamura, Masato Shingyoji, Kazumi Nishino, Eriko Tabata, Naoki Furuya, Shingo Miyamoto, Jun Sakakibara, Mika Nakao, Haruko Daga, Tetsuya Sakai, Yuji Shibata, Hiroki Izumi, Hibiki Udagawa, Yoshitaka Zenke, Kiyotaka Yoh, Koichi Goto
Journal: Annals of Oncology (2022)
MO11-1 Efficacy of durvalumab after chemoradiotherapy with daily low-dose carboplatin for unresectable locally advanced NSCLC
Authors: Kazuki Kawajiri, Yuki Shinno, Masayuki Shirasawa, Daiki Sato, Yuki Takeyasu, Masahiro Torasawa, Yuji Matsumoto, Ken Masuda, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Journal: Annals of Oncology (2022)
PS3-3 Post-operative genomic/epigenomic signatures of circulating tumor DNA and recurrence in colorectal cancer: COSMOS-CRC-01
Authors: Yoshiaki Nakamura, Yuichiro Tsukada, Tatsuro Murano, Nobuhisa Matsuhashi, Manabu Shiozawa, Takeshi Kato, Eiji Oki, Masahiro Goto, Yoshinori Kagawa, Akiyoshi Kanazawa, Takashi Ohta, Akira Ouchi, Hideaki Bando, Xiaotong Zuo, Princy Parsana, Kristin Price, Hiroaki Ikematsu, Takayuki Yoshino
Journal: Annals of Oncology (2022)
MO4-3 Adverse events of sequential tyrosine kinase inhibitor following immune checkpoint inhibitor in advanced NSCLC patients
Authors: Yukiko Shimoda, Jun Miyakoshi, Tatsuya Yoshida, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Journal: Annals of Oncology (2022)
PS4-1 Phase II study of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia
Authors: Koji Sasaki, Hagop Kantarjian, Marina Konopleva, Nitin Jain, Huang Xuelin, Farhad Ravandi, William Wierda, Gautam Borthakur, Nicholas Short, Ghayas Issa, Yesid Alvarado, Naveen Pemmaraju, Guillermo Garcia-Manero, Jennifer Thankachan, Rebecca Garris, Elias Jabbour
Journal: Annals of Oncology (2022)
MO1-6 Characteristics of the tissue obtained in biopsy affecting the success rate of NGS testing in advanced NSCLC patients
Authors: Yuki Takeyasu, Tatsuya Yoshida, Yuji Matsumoto, Yuki Shinno, Ken Masuda, Keigo Uchimura, Tatsuya Imabayashi, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Takaaki Tsuchida, Noboru Yamamoto, Yasushi Yatabe, Yuichiro Ohe
Journal: Annals of Oncology (2022)
P61-2 The efficacy of combination of chemotherapy and immunotherapy compared with immunotherapy alone for NSCLC
Authors: Satoshi Hirano, Hidekazu Takahashi, Amano Hiroyuki, Inazaki Toshiaki, Tsuguko Kuroki, Akira Urano, Fujihiro Kure, Tetsuo Fujita, Makoto Nakamura, Sukeyuki Nakamura
Journal: Annals of Oncology (2022)
O14-1 Pembrolizumab + chemotherapy in Japanese patients with persistent, recurrent, or metastatic cervical cancer: KEYNOTE-826
Authors: Kan Yonemori, Shin Nishio, Tomoka Usami, Shinichiro Minobe, Mayu Yunokawa, Takashi Iwata, Aikou Okamoto, Yoichi Aoki, Hiroaki Itamochi, Munetaka Takekuma, Kenichi Harano, Keiko Yamamoto, Hiroyuki Ugai, Cumhur Tekin, Sarper Toker, Nicoletta Colombo, Keiichi Fujiwara, Kosei Hasegawa
Journal: Annals of Oncology (2022)
P65-1 Clinicopathological feature of T-cell lymphoma in our institute
Authors: Takenori Takahata, Takuto Tachita, Satoru Yamashita, Toru Ebina, Kosuke Kamata, Yu Chen, Kensuke Saito, Atsushi Sato, Kazufumi Yamagata, Yoshiko Tamai, Shinsaku Fukuda
Journal: Annals of Oncology (2022)
MO5-4 Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors
Authors: Yung-Yeh Su, Wei-Hsiang Lee, Jing-Houng Wang, Hung-Wei Wang, Teng-Wei Chen, Bang-Bin Chen, Hsiu J. Ho, Tsung-Hao Liu, Shu-Cheng Chou, Bor-Rong Chen, Tsang-Wu Liu, Li-Tzong Chen, Chun-Ying Wu, Chiun Hsu
Journal: Annals of Oncology (2022)
Can the “female protective effect” liability threshold model explain sex differences in autism spectrum disorder?
Authors: Joseph D. Dougherty, Natasha Marrus, Susan E. Maloney, Benjamin Yip, Sven Sandin, Tychele N. Turner, Din Selmanovic, Kristen L. Kroll, David H. Gutmann, John N. Constantino, Lauren A. Weiss
Journal: Neuron (2022)

Male sex is a strong risk factor for autism spectrum disorder (ASD). The leading theory for a "female protective effect" (FPE) envisions males and females have "differing thresholds" under a "liability threshold model" (DT-LTM). Specifically, this model posits that females require either a greater number or larger magnitude of risk factors (i.e., greater liability) to manifest ASD, which is supported by the finding that a greater proportion of females with ASD have highly penetrant genetic mutations. Herein, we derive testable hypotheses from the DT-LTM for ASD, investigating heritability, familial recurrence, correlation between ASD penetrance and sex ratio, population traits, clinical features, the stability of the sex ratio across diagnostic changes, and highlight other key prerequisites. Our findings reveal that several key predictions of the DT-LTM are not supported by current data, requiring us to establish a different conceptual framework for evaluating alternate models that explain sex differences in ASD.
P77-10 Efficacy of amrubicin after immuno-chemotherapy for extensive-stage small-cell lung cancer
Authors: Ryota Ushio, Haruhiro Saito, Teruhumi Kato, Tetsuro Kondo, Shuji Murakami, Seigo Katakura, Kanako Shinada
Journal: Annals of Oncology (2022)
P16-2 A retrospective analysis of pembrolizumab in patients with high microsatellite instability cholangiocarcinoma
Authors: Takehiro Shimizu, Atsushi Naganuma, Ayako Matsui, Tatsuma Murakami, Yuuki Kanamaya, Dan Zennyoji, Takayoshi Suga, Hiroki Tojima, Yuichi Yamazaki, Satoru Kakizaki, Ken Sato, Toshio Uraoka
Journal: Annals of Oncology (2022)
MO31-4 Phase 1b/2 trial of tucatinib+trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers
Authors: Kohei Shitara, Haeseong Park, Tanios Bekaii-Saab, Sunnie S. Kim, Suneel Kamath, Michael J. Pishvaian, Christopher Chen, David B. Zhen, Joal Mayor, Qianwen Tan, John H. Strickler
Journal: Annals of Oncology (2022)
PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03
Authors: Seock-Ah Im, Binghe Xu, Sung-Bae Kim, Wei-Pang Chung, Yeon Hee Park, Min-Hwan Kim, Ling-Ming Tseng, Chi-Feng Chung, Chiun-Sheng Huang, Jee Hyun Kim, Joanne Wing Yan Chiu, Toshinari Yamashita, Wei Li, Caleb Lee, Soichiro Nishijima, Kyohei Hamada, Yuji Nishiyama, Masahiro Sugihara, Javier Cortés, Hiroji Iwata
Journal: Annals of Oncology (2022)
MO42-3 The stability of angiogenesis-related factors in angiogenesis panel: a prospective observational study
Authors: Toshiharu Hirose, Atsuo Takashima, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Satoru Iwasa, Rie Matsuo, Kimihiko Kawamura, Hiroya Taniguchi, Naoto Tsuchiya, Satoru Otsu, Shuichi Hironaka, Hiromichi Matsushita, Ken Kato
Journal: Annals of Oncology (2022)
MO37-6 Clinical safety of nivolumab 480 mg once every 4 weeks
Authors: Taisuke Hosokai, Motoo Nomura, Masashi Tamaoki, Yosuke Mitani, Kenshiro Hirohashi, Masahiro Yoshioka, Taro Funakoshi, Akira Yokoyama, Junichi Matsubara, Yukiko Mori, Atsushi Yamada, Masashi Kanai, Reiko Kimura, Shigemi Matsumoto, Manabu Muto
Journal: Annals of Oncology (2022)
P66-12 The efficacy of trastuzumab, pertuzumab, and docetaxel in patients with HER-2-positive metastatic breast cancer
Authors: Jean A. Liem, Andree Kurniawan, Joysya Christiano, Teresa M. Argo, Natasha K. Law, Darlene Asafia
Journal: Annals of Oncology (2022)
Neuroscience Cloud Analysis As a Service: An open-source platform for scalable, reproducible data analysis
Authors: Taiga Abe, Ian Kinsella, Shreya Saxena, E. Kelly Buchanan, Joao Couto, John Briggs, Sian Lee Kitt, Ryan Glassman, John Zhou, Liam Paninski, John P. Cunningham
Journal: Neuron (2022)
P73-4 Experience with nivolumab in advanced metastatic gastric cancer
Authors: Kunihiko Wakamura, Hiroki Nakamura, Shingo Matsudaira, Takemasa Hayashi, Hideyuki Miyachi, Toshiyuki Baba, Fumio Ishida, Shin-Ei Kudo
Journal: Annals of Oncology (2022)
P66-3 Safety and efficacy of eribulin in patients with locally advanced or metastatic breast cancer: A phase IV study in India
Authors: Vaibhav Choudhary, Satheesh C. T, Chinmoy K. Bose, Shiv Rajan, Prakash Ss, Chirag Desai, Xiao Lin, Balaji Patil, Sameer Chaudhari, Sudeep Gupta
Journal: Annals of Oncology (2022)
P29-4 Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001)
Authors: Yasuo Kitamura, Hidenori Mizugaki, Yasuyuki Ikezawa, Ryo Morita, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Megumi Furuta, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Satoshi Oizumi
Journal: Annals of Oncology (2022)
O7-4 Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody: JACCRO CC-16
Authors: Tamotsu Sagawa, Akihito Tsuji, Hironaga Satake, Masato Nakamura, Yu Sunakawa, Shotaro Korehisa, Masato Matsuura, Yasuhiro Yuasa, Takashi Mine, Hiroaki Nagano, Kunitoshi Shigeyasu, Tatsuya Kinjo, Masahito Kotaka, Hiroyuki Okuyama, Yutaro Kubota, Mitsugu Kochi, Toshiki Masuishi, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii
Journal: Annals of Oncology (2022)
O9-1 Updated analysis of circulating tumor DNA in advanced genitourinary cancers: SCRUM-Japan MONSTAR SCREEN Project
Authors: Norio Nonomura, Taigo Kato, Takao Fujisawa, Masaki Shiota, Masatoshi Eto, Takahiro Osawa, Takashige Abe, Nobuo Shinohara, Yota Yasumizu, Nobuyuki Tanaka, Mototsugu Oya, Koshiro Nishimoto, Takuji Hayashi, Masashi Nakayama, Satoshi Horasawa, Naomi Kuramoto, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino, Nobuaki Matsubara
Journal: Annals of Oncology (2022)
P63-1 Safety and efficacy of stereotactic body radiotherapy in patients with early stage NSCLC: systematic review
Authors: Mohammad Z. Sabran, Gavin M. Sukendro, Yalimo P. Yogobi, Austa M. Kogoya, Audrey Hamdoyo, Natasha K. Law, Andree Kurniawan
Journal: Annals of Oncology (2022)
P51-1 Prevalence and risk factors of severe weight loss in head and neck cancer patients receiving radiotherapy
Authors: Wilaiporn Chaidee, Supachat Chompoonuch, Veeranat Charoensook, Kanokpis Townamchai, Suttichai Pojananuphap, Manee-Naad Ruangskul
Journal: Annals of Oncology (2022)
MO28-5 Clinical utility of comprehensive genomic profiling for patients with cancer of unknown primary site
Authors: Ryo Kudo, Yoshihito Kano, Rika Noji, Ryota Kakuta, Iichiro Onishi, Kouichiro Kimura, Kousuke Tanimoto, Fuyuki Miya, Takahiro Mitsumura, Noriko Oshima, Yousuke Ariizumi, Tsuyoshi Nakagawa, Toshiaki Ishikawa, Satoshi Miyake, Sadakatsu Ikeda
Journal: Annals of Oncology (2022)
P42-7 FOLFOX-based chemoradiotherapy for locally advanced/metastatic esophageal squamous cell carcinoma with severe dysphagia
Authors: Kazuhiro Shiraishi, Keiji Sugiyama, Mariko Sato, Riko Nishibori, Kyoko Kato, Hiroaki Uda, Akifumi Miyakawa, Ayuko Oguri, Masaya Suenaga, Masaaki Shimada, Masato Kataoka, Eriko Kato, Chiyoe Kitagwa
Journal: Annals of Oncology (2022)
O12-2 The epidemiology of rare cancers from National Cancer Registry in Japan
Authors: Tomoyuki Satake, Chigusa Morizane, Ryoko Rikitake, Shintaro Iwata, Hidekazu Hirano, Dai Ogata, Tatsunori Shimoi, Kazuki Sudo, Seiichi Yoshimoto, Naoya Yamazaki, Yoko Katoh, Takahiro Higashi, Akira Kawai
Journal: Annals of Oncology (2022)
P77-9 Atezolizumab in combination with etoposide plus carboplatin for extensive-stage small-cell lung cancer in our hospital
Authors: Masahide Ota, Akihiro Doi, Syuichi Oya, Masato Tasaki, Hiroyo Ota, Sigeto Hontsu, Motoo Yamauchi, Masanori Yosikawa, Masayuki Takeda, Sigeo Muro
Journal: Annals of Oncology (2022)
P75-5 A phase I intrapatient dose-finding study of MK615 and gemcitabine/nab-paclitaxel with metastatic pancreatic cancer
Authors: Ichiro Moriyama, Fumimasa Takahashi, Shinichiro Matsuda, Fumiyoshi Ikejiri, Masaya Inoue, Kenji Tamura
Journal: Annals of Oncology (2022)
P79-3 Assessment of medication‘s inquiries for medical safety management via risk classification in outpatient chemotherapy
Authors: Kanako Mamishin, Kenji Kawasumi, Junko Tauchi, Masaki Tanaka, Asumi Kaneko, Yoshihiro Iwamoto, Reiko Matsui, Masahito Yonemura, Toshikathu Kawasaki
Journal: Annals of Oncology (2022)
P65-5 The impact of the Geriatric 8 on prognosis in patients aged 65 years and older with DLBCL
Authors: Shin Lee, Kei Fujita, Tsukasaki Hikaru, Oiwa Kana, Negoro Euju, Hara Takeshi, Tsurumi Hisashi, Ueda Takanori, Yamauchi Tkahiro
Journal: Annals of Oncology (2022)
P60-1 Safety and feasibility of hyper short-hydration using furosemide in cisplatin-based chemotherapy
Authors: Yasushi Fukuda, Hiroshige Yoshioka, Tae Hata, Yasuyoshi Washio, Koji Furuuchi, Reoto Takei, Akio Yamasaki, Masaharu Aga, Shogo Kumagai, Takashi Nishihara, Tomoki Tanaka, Akira Yamagata, Masashi Momose, Yosuke Nakanishi, Yuta Yamanaka, Toshihiko Kaneda, Takashi Niwa, Toshihide Yokoyama, Takayasu Kurata, Tadashi Ishida
Journal: Annals of Oncology (2022)
MO44-4 Phase II study of nivolumab rechallenge in advanced NSCLC pts who responded to prior anti-PD-1/L1 inhibitors; WJOG 9616L
Authors: Satoru Miura, Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Hidetoshi Hayashi, Akito Hata, Yukihiro Toi, Yoshimasa Shiraishi, Nobuaki Mamesaya, Yuki Sato, Naoki Furuya, Yasuhiro Koh, Toshihiro Misumi, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Annals of Oncology (2022)
MO5-6 Maintenance treatment with gemcitabine after gemcitabine plus Nab-paclitaxel in advanced pancreatic cancer
Authors: Tomoko Kodama, Junichi Nakazawa, Masahiro Kawahira, Akihiro Ymasuji, Yuji Iwashita, Takeshi Hori, Machiko Kawahira, Shiho Arima, Hirohito Tubouchi, Akio Ido
Journal: Annals of Oncology (2022)
P21-6 Outcome of palliative endotracheal tube withdrawal in terminal illness patient with or without cancer
Authors: Supachat Chompoonuch, Jittima Phativitayaporn, Saowanee Preamthong, Supatra Kidwisala, Achaporn Vichitranuja, Chutima Upachar
Journal: Annals of Oncology (2022)
P68-5 Prospective trial of comprehensive genomic profiling for patients with chemotherapy-naïve cancer (FIRST-Dx trial)
Authors: Junichi Matsubara, Kumi Mukai, Hidenori Kage, Katsutoshi Oda, Ryo Kudo, Sadakatsu Ikeda, Hiromichi Ebi, Kei Muro, Ryuji Hayashi, Nahomi Tokudome, Nobuyuki Yamamoto, Manabu Muto
Journal: Annals of Oncology (2022)
P1-11 Real-world treatment patterns in multiple myeloma: Japan MDV Claims Database analysis (2016-2020)
Authors: Kenshi Suzuki, Amy Buchanan-Hughes, Alvin Ng, Yan Ran Wee, Iro Chatzidaki, Jose Garnica, Eiji Kawahara, Fumiko Ueki, Christopher Kim, Nicholas Despiegel
Journal: Annals of Oncology (2022)
P44-4 Analysis of Oncomine Dx Target Test at our hospital and its usefulness in clinical practice
Authors: Shinji Chiba, Shinnosuke Oura, Katsuya Chou, Tatsuya Hashimoto, Hirotaka Saikawa, Takashi Ito, Ami Matsumoto, Itaru Fujimura, Masachika Akiyama, Yu Utsumi, Hiromi Nagashima, Naoki Yanagwa, Tamotsu Sugai, Makoto Maemondo
Journal: Annals of Oncology (2022)
P29-5 Efficacy of immune checkpoint inhibition in patients with advanced NSCLC with KRAS, MET, other minor driver alterations
Authors: Yuji Uehara, Kageaki Watanabe, Taiki Hakozaki, Kie Mirokuji, Kana Hashimoto, Kosuke Narita, Shoko Kawai, Makiko Yomota, Yukio Hosomi
Journal: Annals of Oncology (2022)
PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup
Authors: Masato Takahashi, Javier Cortés, Rebecca Dent, Lajos Pusztai, Heather Mcarthur, Sherko Kümmel, Carsten Denkert, Yeon Hee Park, Seock-Ah Im, Jin-Hee Ahn, Hirofumi Mukai, Chiun-Sheng Huang, Shin-Cheh Chen, Min Hwan Kim, Liyi Jia, Xin Tong Li, Konstantinos Tryfonidis, Vassiliki Karantza, Hiroji Iwata, Peter Schmid
Journal: Annals of Oncology (2022)
MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study
Authors: Keunchil Park, Joshua Sabari, Eric B. Haura, Catherine A. Shu, Alexander Spira, Ravi Salgia, Karen L. Reckamp, Rachel E. Sanborn, Ramaswamy Govindan, Joshua M. Bauml, Joshua C. Curtin, John Xie, Amy Roshak, Patricia Lorenzini, Dawn Millington, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho
Journal: Annals of Oncology (2022)
T-bet+ B cells accumulate in adipose tissue and exacerbate metabolic disorder during obesity
Authors: Thomas Hägglöf, Carlo Vanz, Abigail Kumagai, Elizabeth Dudley, Vanessa Ortega, McKenzie Siller, Raksha Parthasarathy, Josh Keegan, Abigail Koenigs, Travis Shute, Elizabeth A Leadbetter
Journal: Cell Metabolism (2022)
P17-5 Early onset of anorexia-cachexia related worsening of cachexia symptoms during chemotherapy for pancreatic cancer
Authors: Shuichi Mitsunaga, Kanae Inoue, Tomonao Taira, Hiroki Eguchi, Kei Okumura, Taro Shibuki, Kazuo Watanabe, Mitsuhito Sasaki, Hiroshi Imaoka, Masafumi Ikeda
Journal: Annals of Oncology (2022)
O19-2 Comparison of clinical utility between whole-exome sequencing and targeted sequencing (PleSSision-WET study)
Authors: Hideyuki Hayashi, Shigeki Tanishima, Kaori Mochida, Tomoka Fujikura, Sachiko Hagiwara, Emmy Yanagita, Hiroshi Yamada, Ryutaro Kawano, Kohei Nakamura, Marin Ishikawa, Yasutaka Kato, Eriko Aimono, Mitsuho Imai, Arisa Ueki, Hiroshi Nishihara
Journal: Annals of Oncology (2022)